IDT Australia : FY22 Interim Results and Investor Update

onlyuse IDT AUSTRALIA LIMITED

ersonal2022 INTERIM RESULTS AND INVESTOR UPDATE

FOR THE SIX MONTHS ENDED 31 DECEMBER 2021

23 February 2022

ersonal use only

Key Operational Highlights

IDT Maintaining Profitability, Strong Cash Balance

• H1 FY`22: Revenue year-on-year increase of 74% to $8.56 million, EBITDA of $1.97 million and $1.21 million Profit
• H1 FY`22 closing cash balance of $13.31 million

Sterile Manufacturing Licence Secured From The Therapeutic Goods Administration

• Successfully executed the Letter Agreement with the Australian Government, Department of Health, to bring IDT's cGMP sterile manufacturing facility into a state of readiness
• Sterile manufacturing licence secured from Therapeutic Goods Administration

IDT Manufactures Australia's First cGMP mRNA Drug Product

• IDT successfully manufactured the Monash University / Doherty Institute developed mRNA COVID-19 receptor binding domain vaccine drug product. Australia's first locally developed and manufactured mRNA COVID-19 vaccine candidate

IDT's Sovereign Manufacturing Initiatives

• IDT was unsuccessful (along with all ATM respondents) in its submission to the Australian Government's Approach To Market- Onshore mRNA Manufacturing Capability
• IDT's Modern Manufacturing Initiative (Collaboration and Translation Stream) funding opportunities remain live

Continuing To Execute On The Company's Medicinal Cannabis Manufacturing Plan

• Expanding stability data for flower-in-bottle and oil-in-bottle products
• Advancing a pipeline of new product development opportunities

Key Financial Highlights

Strong cash balance of $13.31 million onlyYear-on-year Revenue increase of 74% to $8.56 million

Positive EBITDA of $1.97 million achieved for the half year

$1.21 million Profit for the half year improved by $8% use0.5¢ Earnings per share

Res lts support IDT's objective to progress the business

to sustainable profitability ersonal

	Half Year ended 31
	December ('$000)	2021	2020	Variance
	Revenue	8,559	4,911	3,648	74%
	EBITDA	1,974	1,927	47	2%
	NPAT	1,214	1,124	90	8%
	Basic earnings per share	0.5¢	0.5¢	-	-

Sterile Manufacturing:

Australia's First cGMP mRNA Drug Product

ersonal use only

• During the Half Year in review IDT engaged with the Therapeutic Goods Administration (TGA) to successfully deliver the Sterile Readiness Letter Agreement finalised with the Australian Government, Department of Health
• A Sterile Manufacturing Licence (the Company's first ever sterile licence) has been secured from the TGA
• IDT's flagship sterile manufacturing facility is now being maintained in a state of sterile readiness
• IDT utilised its sterile manufacturing facilities and capabilities to successfully manufacture Australia's first cGMP mRNA COVID-19 vaccine candidate, destined for clinical trials
• The Monash University / Doherty Institute developed mRNA COVID-19 receptor binding domain vaccine is Australia's first locally developed mRNA COVID-19 vaccine candidate

Goal:

IDT's goal is to leverage its existing sterile facilities and capabilities to play a role in Australia's emerging mRNA manufacturing ecosystem and to provide other fee-for-service sterile manufacturing services.

Sovereign Manufacturing

Approach-To-Market Bid Unsuccessful
Modern Manufacturing Initiative Bids Remain Live
only
 IDT put forward its existing and licenced sterile manufacturing facility in support of a submission to the Australian
use	Government's Onshore mRNA Manufacturing Capability: Approach To Market (ATM). The Company's bid was for IDT
to deliver a population scale end-to-end mRNA Australian sovereign manufacturing solution
 All ATM submissions (including IDT's) were unsuccessful
 IDT has ongoing support from industry and academia, including The Peter Doherty Institute for Infection and
	Immunity, Monash University, University of Melbourne and the Australian National University to build an mRNA
ersonal	manufacturing ecosystem in Australia. This support underpins IDT's submissions to the Australian Government's
Modern Manufacturing Initiative Collaboration and Translation Stream grants (MMI)

 IDT's MMI Collaboration and Translation Stream opportunities remain live